Shield Therapeutics plc SHIEF
0.04 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.0419 Day range 0.0467
0.0419 52-week range 0.1679
- YTD
- -70.27%
- 1 year
- -55.85%
News
seekingalpha.com Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript
proactiveinvestors.co.uk Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States…
proactiveinvestors.co.uk Shield Therapeutics jumps 11% as losses narrow and profitability target held Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) rose 11% to 4.89p on Thursday after the pharmaceutical company reported sharply narrower half-year losses and reaffirmed its aim of reaching…
seekingalpha.com Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
proactiveinvestors.co.uk Shield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track' Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) told investors it remained profitable in the first half as a China milestone payment and higher royalties lifted revenue 41% to $30.4 million, with the…
seekingalpha.com Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
proactiveinvestors.com Shield Therapeutics drops as CFO exits and Medicaid concerns weigh Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...
proactiveinvestors.co.uk Shield Therapeutics drops as CFO exits and Medicaid concerns weigh Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market…
proactiveinvestors.co.uk Shield shares jump after FDA extends Accrufer exclusivity Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the…
seekingalpha.com Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
proactiveinvestors.co.uk Shield Therapeutics shares positive efficacy data for iron deficiency treatment Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has announced positive results from its Phase 3 pediatric FORTIS trial of ferric maltol (ACCRUFeR). The trial tested children and adolescents with iron…
proactiveinvestors.co.uk Shield Therapeutics lifted as US FDA extends Accufer approval Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) shares climbed in Thursday's early trade after it announced that the US Food and Drug Administration has accepted its submission to extend the label for…
proactiveinvestors.co.uk Shield Therapeutics shares surge 21% as ACCRUFeR revenues double Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) saw its share price rise 21% following a strong second-quarter trading update. The company reported that net revenues from its iron deficiency…
proactiveinvestors.co.uk Shield Therapeutics rises on Japan licensing deal for iron deficiency drug Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a licensing agreement that will see its iron deficiency treatment ACCRUFeR…
proactiveinvestors.co.uk Shield Therapeutics edges closer to profitability as US sales surge Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is gaining momentum. The company, known for its oral iron supplement ACCRUFeR, has reported a strong end to 2024, with US sales driving record revenues…
proactiveinvestors.co.uk Shield Therapeutics shares rise on the back of $10m fundraiser Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose in afternoon trading after the company announced a $10 million fundraising commitment from its largest investor, AOP Health…
proactiveinvestors.co.uk Shield Therapeutics unveils premium fundraiser Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a specialist in iron deficiency treatments, said its largest investor, AOP Health International, is backing a $10 million fundraiser. It will subscribe…
proactiveinvestors.co.uk Shield Therapeutics ‘on track for 2024' - analyst Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed…
proactiveinvestors.co.uk Shield Therapeutics up 27% after impromptu trading update Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) surged 27% in early trading after strong October sales of its iron deficiency drug ACCRUFeR, driven by an increase in net selling price to…
proactiveinvestors.co.uk Shield Therapeutics on course in China as sales growth continues Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)) has reported strong sales of iron deficiency drug ACCRUFeR in October, bolstered by an increase in the net selling price to over $225 per prescription,…